Zacks reaffirmed their outperform rating on shares of Allergan (NYSE:AGN) in a research note issued to investors on Thursday, AR Network reports. The firm currently has a $138.00 price target on the stock.
Zacks has also taken action a number of other healthcare stocks recently. The firm downgraded shares of Sagent Pharmaceuticals Inc. from an outperform rating to a neutral rating. Their analysts now have a $22.70 price target on that stock. Also, Zacks reiterated its neutral rating on shares of Perrigo Co.. They have a $154.00 price target on that stock. Finally, Zacks reiterated its neutral rating on shares of AbbVie Inc.. They have a $50.00 price target on that stock.
Allergan (NYSE:AGN) traded up 0.43% during mid-day trading on Thursday, hitting $117.88. 1,382,405 shares of the company’s stock traded hands. Allergan has a one year low of $81.33 and a one year high of $123.83. The stock has a 50-day moving average of $113.9 and a 200-day moving average of $97.19. The company has a market cap of $35.029 billion and a P/E ratio of 35.58.
Allergan (NYSE:AGN) last announced its earnings results on Tuesday, February 4th. The company reported $1.12 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.34 by $0.22. The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.65 million. During the same quarter last year, the company posted $1.15 earnings per share. Allergan’s revenue was up 14.4% compared to the same quarter last year. On average, analysts predict that Allergan will post $5.45 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, March 21st. Shareholders of record on Friday, February 28th will be given a dividend of 0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.17%. The ex-dividend date of this dividend is Wednesday, February 26th.
Other equities research analysts have also recently issued reports about the stock. Analysts at Citigroup Inc. upgraded shares of Allergan from a neutral rating to a buy rating in a research note to investors on Tuesday. They now have a $130.00 price target on the stock, up previously from $95.00. Separately, analysts at SunTrust upgraded shares of Allergan from a neutral rating to a buy rating in a research note to investors on Friday, January 17th. They now have a $150.00 price target on the stock, up previously from $94.00. Finally, analysts at Morgan Stanley reiterated an equal weight rating on shares of Allergan in a research note to investors on Wednesday, January 15th. They now have a $94.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of Buy and an average price target of $118.10.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.